Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Therapy

Oral or subcutaneous methotrexate for rheumatoid arthritis?

This article has been updated

Although methotrexate is the main therapy for rheumatoid arthritis, surprisingly little is known about the optimal route of administration; bioavailability of methotrexate has been shown to vary accordingly. In terms of delaying a switch to biologic therapy, is the subcutaneous route superior to oral methotrexate therapy?

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Change history

  • 17 September 2014

    In the original version of this article published online the competing interest statement for S.A. was missing. This error has now been corrected in the HTML and PDF versions of the article.

References

  1. Curtis, J. R. et al. Use of oral and subcutaneous methotrexate in rheumatoid arthritis patients in the United States. Arthritis Care Res. (Hoboken) http:dx.doi.org/10.1002/acr.22383.

  2. Visser, K. et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systemic literature research and expert opinion of a broad international panel of rheumatologists in the 3E initiative. Ann. Rheum. Dis. 68, 1086–1089 (2009).

    Article  CAS  PubMed  Google Scholar 

  3. Singh, J. A. et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. (Hoboken) 64, 625–639 (2012).

    Article  CAS  Google Scholar 

  4. Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease modifying antirheumatic drugs: 2013 update. Ann. Rheum. Dis. 73, 492–509 (2014).

    Article  CAS  Google Scholar 

  5. Hoekstra, M. et al. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J. Rheumatol. 31, 645–648 (2004).

    CAS  PubMed  Google Scholar 

  6. Schiff, M. H., Jaffe, J. S. & Freundlich, B. Head-to-head, randomized, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration. Ann. Rheum. Dis. 73, 1549–1551 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Bakker, M. F. et al. Are switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis? A post hoc analysis of the CAMERA study. Ann. Rheum. Dis. 69, 1849–1852 (2010).

    Article  CAS  PubMed  Google Scholar 

  8. Braun J. et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 58, 73–81 (2008).

    Article  CAS  PubMed  Google Scholar 

  9. Hazlewood, G. et al. Subcutaneous delivery of methotrexate is associated with improved treatment survival compared to oral administration for the initial treatment of patients with early rheumatoid arthritis [abstract]. Arthritis Rheum. 65 (Suppl. 10), 627 (2013).

    Google Scholar 

  10. Fitzpatrick, R., Scott, D. G. & Keary, I. Cost-minimisation analysis of subcutaneous methotrexate versus biologic therapy for the treatment of patients with rheumatoid arthritis who had have had an insufficient response or intolerance to oral methotrexate. Clin. Rheumatol. 32, 1605–1612 (2013).

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors acknowledge the excellent secretarial assistance of S. Gillard.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Edward C. Keystone.

Ethics declarations

Competing interests

E.C.K. declares that he is a consultant for Antares Pharma. S.A. declares no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Alsaeedi, S., Keystone, E. Oral or subcutaneous methotrexate for rheumatoid arthritis?. Nat Rev Rheumatol 10, 578–579 (2014). https://doi.org/10.1038/nrrheum.2014.129

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2014.129

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing